Find clinical trials for Leukemia. Search for oncology clinical trials in different cities and states across the United States.
Sponsor:
Cyclacel Pharmaceuticals, Inc.
Location:
Code:
NCT01211457
Conditions
Acute Myeloid Leukemia
Myelodysplastic Syndromes
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
sapacitabine and decitabine (Part 1 - completed)
sapacitabine and venetoclax (Part 2 - recruiting)
Sponsor:
University of Utah
Location:
Code:
NCT06227026
Conditions
Acute Lymphoblastic Leukemia
Diffuse Large B Cell Lymphoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Anti-CD19 CAR-T cells
Sponsor:
M.D. Anderson Cancer Center
Location:
Code:
NCT00501826
Conditions
T Acute Lymphoblastic Leukemia
T Lymphoblastic Lymphoma
Eligibility Criteria
Sex: All
Age: 0 - 70+
Healthy Volunteers: Not accepted
Interventions
Cyclophosphamide
Cytarabine
Dexamethasone
Doxorubicin Hydrochloride
Mercaptopurine
Sponsor:
Masonic Cancer Center, University of Minnesota
Location:
Code:
NCT03314974
Conditions
Acute Leukemia
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Lymphoma
Chronic Myelogenous Leukemia
Eligibility Criteria
Sex: All
Age: 0 - 60
Healthy Volunteers: Not accepted
Interventions
HSCT with TBI Regimen
HSCT with Non-TBI Regimen
Sponsor:
Arog Pharmaceuticals, Inc.
Location:
Code:
NCT03258931
Conditions
Newly Diagnosed FLT3 Mutated AML
Eligibility Criteria
Sex: All
Age: 18 - 60
Healthy Volunteers: Not accepted
Interventions
Crenolanib
Midostaurin
Cytarabine
Duanorubicin
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT06311227
Conditions
Recurrent Hairy Cell Leukemia
Recurrent Hairy Cell Leukemia Variant
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Biospecimen Collection
Bone Marrow Aspiration
Bone Marrow Biopsy
Computed Tomography
Magnetic Resonance Imaging
Sponsor:
Baylor College of Medicine
Location:
Code:
NCT01853631
Conditions
Non-Hodgkin Lymphoma
Chronic Lymphocytic Leukemia
Acute Lymphocytic Leukemia
Eligibility Criteria
Sex: All
Age: 0 - 70+
Healthy Volunteers: Not accepted
Interventions
Dose Escalation Phase:CD19.CAR/28 and CD19.CAR/28137 T cells
Expansion Phase: CD19.CAR/28 and CD19.CAR/28137 T cells
Sponsor:
Sawa Ito, MD
Location:
Code:
NCT06529731
Conditions
Acute Myeloid Leukemia
Myelodysplastic Syndromes
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Interferon gamma-1b
Donor Leukocyte Infusion (DLI)
Sponsor:
MacroGenics
Location:
Code:
NCT05362773
Conditions
Leukemia, Acute Myeloid
Myelodysplastic Syndromes
Classical Hodgkin Lymphoma
Leukemia, B-cell
Leukemia, Hairy Cell
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
MGD024
Sponsor:
Dr. Melody Smith, MD, MS
Location:
Code:
NCT05507827
Conditions
Lymphoid Leukemia
Eligibility Criteria
Sex: All
Age: 18 - 65
Healthy Volunteers: Not accepted
Interventions
Allogeneic donor-derived T-cells transduced with bivalent lentiviral vector (CD19/CD22-BBz) chimeric antigen receptor (CAR)
Treg CD34+HSPC (Orca-T)
Clinical trials for leukemia are research studies designed to evaluate new treatments, therapies, or diagnostic methods for different types of leukemia, a group of cancers that affect the blood and bone marrow. These trials aim to discover more effective ways to treat leukemia, manage its symptoms, and improve patient outcomes. They may involve testing new drugs, combinations of existing treatments, targeted therapies, immunotherapies, or novel approaches like gene therapy.
Leukemia clinical trials are crucial because they drive advancements in treatment by testing new therapies, improving existing ones, and exploring novel approaches to manage and potentially cure the disease. These trials provide essential data on the safety and effectiveness of new treatments, which can lead to better outcomes and fewer side effects compared to current options.
Researchers have a number of options available when it comes to choosing the type of clinical trial that should be used for a leukemia research study.
Diagnostic trials in leukemia clinical research focus on developing or refining techniques for detecting and diagnosing the disease more accurately and earlier. These trials test new diagnostic tools, such as imaging technologies, blood tests, or genetic assays, to improve the precision of leukemia detection, identify specific subtypes, and monitor disease progression.
By enhancing diagnostic methods, these trials aim to enable earlier intervention, tailor treatments more effectively, and ultimately improve patient outcomes and survival rates.
Genetic and biomarker studies in leukemia focus on identifying specific genetic mutations, variations, and molecular markers associated with the disease. By analyzing the genetic profile of leukemia cells and patients, researchers can uncover the underlying mechanisms that drive the disease's development and progression. This information is crucial for advancing personalized medicine, as it enables healthcare providers to tailor treatments to the unique genetic makeup of each patient.
Interventional trials for leukemia actively test new treatments or therapeutic approaches by administering experimental drugs or therapies to participants. These trials evaluate the effectiveness and safety of new drugs, compare new treatments with standard options, explore combination therapies, and assess innovative strategies like stem cell transplants or gene therapy. They also help determine optimal dosages and administration schedules.
Researchers can use prevention trials for leukemia to identify strategies to reduce the risk of developing the disease or to prevent its recurrence in patients who are in remission. These trials may test interventions such as medications, lifestyle changes, or vaccines in individuals at high risk for leukemia, such as those with a family history or predisposing conditions.
By evaluating these preventive measures, the trials seek to find effective ways to lower the incidence of leukemia or delay its onset, ultimately improving long-term outcomes and quality of life for those at risk.
Just as many clinical trials can pose risks or considerations, leukemia clinical trials can offer a number of benefits for participants too.
Participating in a clinical trial for leukemia offers several benefits, including access to cutting-edge treatments and therapies that may not be available outside the trial. Participants receive close monitoring and care from specialized medical teams, which can lead to early detection of side effects and more personalized treatment adjustments.
Leukemia clinical trials also contribute to valuable research, advancing medical knowledge and supporting the development of better future treatments. Additionally, involvement in a trial provides an opportunity to potentially benefit from new interventions that could improve outcomes and quality of life.
When deciding whether to participate in a clinical trial for leukemia, it’s important to think about the risks and considerations, such as the potential for unknown side effects from experimental treatments, which may be worse or different from standard therapies. There is also the risk that the new treatment may not be effective, potentially leading to a lack of improvement or worsening of the condition.
Participants might also face rigorous schedules for medical visits and tests, which can be time consuming and inconvenient. It’s possible that participants could have uncertainties about coverage of trial-related expenses, as well as the emotional stress of navigating an experimental treatment.
Worried about the risks of participating in a clinical trial? Delve into our comprehensive guide to gain insights into the potential outcomes of participating. Learn about potential risks, benefits, and safety considerations to make an informed decision about your participation in a clinical trial.
Specific criteria for involvement in a leukemia clinical trial depends on the trial’s objectives and design, but researchers often include factors such as the type and stage of leukemia, overall health, and prior treatments. Some trials may focus on particular age groups, such as children or adults, while others might target specific genetic mutations or risk factors. For most leukemia clinical trials, a leukemia diagnosis or a high risk of developing it is usually the first requirement.
In addition to patients with active leukemia, some trials may also include healthy volunteers for comparison purposes or individuals in remission to test preventive measures or recurrence interventions.
When participating in a clinical trial for leukemia, you can expect to undergo a detailed screening process to confirm eligibility and provide informed consent about the study's purpose, procedures, risks, and benefits. You may receive experimental treatments or therapies, and will be closely monitored through regular medical visits, tests, and assessments to evaluate the effectiveness and safety of the intervention.
The trial may involve strict protocols, including rigorous schedules and adherence to treatment regimens. While participation in a leukemia clinical trial potentially offers access to innovative treatments and specialized care, it also involves the potential for unknown side effects and uncertainties regarding treatment outcomes.
Enrolling in a clinical trial studying leukemia through our platform is a straightforward and user-friendly process. Here's how to get started: